Abstract
Deubiquitinating enzymes (or DUBs) attack the ubiquitin-based isopeptide bond, thus counteracting ubiquitinprotein ligase activity in vivo. By disassembling ubiquitin-substrate and ubiquitin-ubiquitin covalent links, deubiquitinating enzymes exert a very powerful control of many signaling processes within the ubiquitin-proteasome system (UPS). Very active research in this field in the last decade shows that deubiquitinating enzymes play important regulatory roles in aspects relevant to cancer, such as proteasome activity, p53 stability, the regulation of fanconi anemia related proteins, tumor cell apoptosis induction, to mention a few. Thus, deubiquitinating enzymes have emerged as interesting drug targets in cancer research. Here, the pharmacological inhibition of DUBs and its potential effect in cancer treatment are reviewed.
Keywords: Deubiquitinating enzymes, DUBs, inhibitors, proteasome, small-molecule, ubiquitin specific proteases, USP1, USP7, USP8, USP9x, USP14.
Current Cancer Drug Targets
Title:Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Volume: 14 Issue: 6
Author(s): Bernat Crosas
Affiliation:
Keywords: Deubiquitinating enzymes, DUBs, inhibitors, proteasome, small-molecule, ubiquitin specific proteases, USP1, USP7, USP8, USP9x, USP14.
Abstract: Deubiquitinating enzymes (or DUBs) attack the ubiquitin-based isopeptide bond, thus counteracting ubiquitinprotein ligase activity in vivo. By disassembling ubiquitin-substrate and ubiquitin-ubiquitin covalent links, deubiquitinating enzymes exert a very powerful control of many signaling processes within the ubiquitin-proteasome system (UPS). Very active research in this field in the last decade shows that deubiquitinating enzymes play important regulatory roles in aspects relevant to cancer, such as proteasome activity, p53 stability, the regulation of fanconi anemia related proteins, tumor cell apoptosis induction, to mention a few. Thus, deubiquitinating enzymes have emerged as interesting drug targets in cancer research. Here, the pharmacological inhibition of DUBs and its potential effect in cancer treatment are reviewed.
Export Options
About this article
Cite this article as:
Crosas Bernat, Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy, Current Cancer Drug Targets 2014; 14 (6) . https://dx.doi.org/10.2174/1568009614666140725090620
DOI https://dx.doi.org/10.2174/1568009614666140725090620 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and
Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics
Analysis
MicroRNA Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
CNS & Neurological Disorders - Drug Targets Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Tumor-Targeted Inhibition by a Novel Strategy - Mimoretrovirus Expressing siRNA Targeting the Pokemon Gene
Current Cancer Drug Targets The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Fluorescent GPCR Ligands as New Tools in Pharmacology-Update, Years 2008- Early 2014
Current Medicinal Chemistry